Observational studyBMC ophthalmology2025
Axial length and IOL power stability in macular edema treated with anti-VEGF: a preliminary study using OLCR biometry.
Observational study in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effect of Shallow Anterior Chamber on Postoperative Refractive Status in Patients of Age-Related Cataract.Journal of ophthalmology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate axial length (AxL) variability and intraocular lens (IOL) power stability in macular edema (ME) patients undergoing intravitreal anti-VEGF therapy using Lenstar biometry.
methodsIn this preliminary observational study, 32 patients (64 eyes) with unilateral macular edema (ME) due to diabetic retinopathy or retinal vein occlusion were evaluated. AxL and IOL power were measured pre- and post-treatment using LenStar OLCR biometry. Three measurement strategies were employed: automated (AxLα), manually adjusted (AxLβ), and CRT-corrected (AxLγ). Four experienced ophthalmologists manually repositioned A-scan markers. Fellow eyes were assessed longitudinally. Statistical analyses included paired t-tests, intraclass correlation coefficients, and correlation tests.
resultsThe mean patient age was 61.38 ± 9.44 years. Anti-VEGF treatment significantly reduced mean CRT from 444.47 ± 121.16 μm to 374.50 ± 98.90 μm (p < 0.001). The mean preoperative and postoperative AxL were 23.11 ± 0.72 mm and 23.10 ± 0.72 mm, respectively (p = 0.091), showing no significant change. However, in cases with CRT > 300 μm, AxL reduction was statistically significant (p = 0.044), though IOL power calculations remained stable (p = 0.401). Interobserver agreement was high for AxL and IOL power measurements, with intraclass correlation coefficients of 0.854 preoperatively and 0.989 postoperatively. Manual adjustments resulted in significant AxL differences between pre- and post-treatment periods (p < 0.001), while automated Lenstar measurements remained consistent. Fellow eyes IOL and AxL remained identical in both preoperative and postoperative sessions (p = 0.323 for IOL and p = 0.287 for AxL).
conclusionThis preliminary observational study suggests that AxL and IOL power measurements remain stable following anti-VEGF therapy in most ME cases. Small but consistent AxL changes in eyes with high CRT may indicate a structural threshold for biometric variability. OLCR-based biometry remains reliable in real-world practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.